Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical in vitro diagnostics for kidney disease, announces that it will release its preliminary results for the year ended... read more →
Download full announcement Intended appointment of an additional Non-Executive Director Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical in vitro diagnostics for kidney disease, announces the expansion... read more →
Download full announcement For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2019, the Company's issued and fully... read more →
Download full announcement RenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX ™ RenalytixAI plc (AIM: RENX), a developer of... read more →
Download full announcement Renalytix AI welcomes US Administration’s dedication to advancing American kidney health Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease,... read more →
Download full announcement Data development plan review continues with FDA under Breakthrough Device Designation Process Performance meets or exceeds targets for identifying Rapid Kidney Function Decline in patients with Type... read more →
Download full announcement Published data on blood diagnostic for subclinical acute kidney transplant rejection and potential to tailor immunosuppressive therapy Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled... read more →
Download full announcement CPT Code a key component for reimbursement from private medical insurance and Medicare Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney... read more →